Extended high efficacy of the combination sulphadoxine-pyrimethamine with artesunate in children with uncomplicated falciparum malaria on the Benin coast, West Africa

Malaria Journal

Volumn 8, Issue 1, 2009, Pages

  Nahum, Alain ^a   Erhart, Annette ^b   Ahounou, Daniel ^a   Bonou, Désiré ^a   Van Overmeir, Chantal ^b   Menten, Joris ^b   Akogbeto, Martin ^a   Coosemans, Marc ^b   Massougbodji, Achille ^c   D'Alessandro, Umberto ^b  

^a Centre de Recherches Entomologiques de Cotonou   (Benin)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c UNIVERSITY OF ABOMEY CALAVI   (Benin)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ARTESUNATE; CHLOROQUINE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; GLYCINE; QUININE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

ARTICLE; BENIN; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FOLLOW UP; GENE MUTATION; GENOTYPE; HAPLOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; PARASITE GENOTYPING; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ANALYSIS OF VARIANCE; ANIMAL; COHORT ANALYSIS; DRUG COMBINATION; DRUG EFFECT; FEMALE; FEVER; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; MALE; PARASITOLOGY; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIMALARIALS; ARTEMISININS; BENIN; CHILD, PRESCHOOL; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; FEVER; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PYRIMETHAMINE; SULFADOXINE; TREATMENT OUTCOME;

EID: 62149106204     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-37     Document Type: Article

References (44)

1. Ministère de la Santé Atelier de consensus sur le changement de la politique de traitement antipaludique. Programme National de Lutte contre le Paludisme Cotonou: DNPS 2004 1 10
2. Ministère de la Santé Politique Nationale de Lutte contre le Paludisme et cadre stratégique de mise enuvre. Programme National de Lutte contre le Paludisme Cotonou. DNPS 2005 1 50
3. Ministère de la Santé Programme National de Lutte contre le Paludisme Cotonou. DNPS 1992
4. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. D Kyabayinze A Cattamanchi MR Kamya PJ Rosenthal G Dorsey, Am J Trop Med Hyg 2003 69 247 52 14628939
5. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. JG Kublin FK Dzinjalamala DD Kamwendo EM Malkin JF Cortese LM Martino RA Mukadam SJ Rogerson AG Lescano ME Molyneux PA Winstanley P Chimpeni TE Taylor CV Plowe, J Infect Dis 2002 185 380 388 10.1086/338566 11807721
6. World Health Organization, Antimalarial drug combination therapy. Report of WHO technical consultation, 4-5 April. Geneva, (WHO/CDS/RBM/2001.35) WHO, Geneva 2001
7. World Health Organization, Guidelines for the treatment of malaria WHO, Geneva 2006 http://whqlibdoc.who.int/publications/2006/9241546948-eng.pdf
8. Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine- pyrimethamine plus amodiaquine for treating uncomplicated malaria. H Bukirwa J Critchley, Cochrane Database Syst Rev 2006 1 CD004966 16437507
9. Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: ameta-analysis. CO Obonyo EA Juma BR Ogutu JM Vulule J Lau, Trans R Soc Trop Med Hyg 2007 101 117 126 10.1016/j.trstmh.2006.07.001 16978673
10. Antimalarial drug combination policy: a caveat. C Wongsrichanalai K Thimasarn J Sirichaisinthop, Lancet 2000 24 2245 2247 10.1016/S0140-6736(00) 02416-8
11. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. F Nosten M van Vugt R Price C Luxemburger KL Thway A Brockman R McGready F ter Kuile S Looareesuwan NJ White, Lancet 2000 22 297 302 10.1016/S0140- 6736(00)02505-8
12. Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa. A Nahum A Erhart D Gazard C Agbowai C Van Overmeir H van Loen J Menten M Akogbeto M Coosemans A Massougbodji U D'Alessandro, Malar J 2007 6 170 18154655 10.1186/1475-2875-6-170
13. Etude des aspects épidémiologiques du paludisme ctier lagunaire au Bénin. M Akogbeto, Thèse de Doctorat ès-Science Université de Paris XI 1992
14. Malaria transmission in the lagoon area of Cotonou, Benin. M Akogbeto D Modiano A Bosman, Parassitologia 1992 34 147 154 1339969
15. Reduced efficacy of insecticide-treated nets and indoor residual spraying for malaria control in pyrethroid resistance area, Benin. R N'Guessan V Corbel M Akogbéto M Rowland, Emerg Infect Dis 2007 13 199 206 17479880
16. Severe falciparum malaria. World Health Organization, Trans R Soc Trop Med Hyg 2000 94 Suppl 1 1 90 10.1016/S0035-9203(00)90300-6
17. World Health Organization, Assessment and monitoring of antimalarial drug efficay for the treatment of uncomplicated falciparum malaria Geneva; World Health Organization 2003
18. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. CV Plowe A Djimde M Bouare O Doumbo TE Wellems, Am J Trop Med Hyg 1995 52 565 568 7611566
19. Frequency of cross-fertilization in the human malaria parasite Plasmodium falciparum. LC Ranford-Cartwright P Balfe R Carter D Walliker, Parasitology 1993 107 11 18 8355994
20. Plasmodium falciparum : detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. MT Duraisingh J Curtis DC Warhurst, Exp Parasitol 1998 89 1 8 10.1006/expr.1998.4274 9603482
21. In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. K Stepniewska WR Taylor M Mayxay R Price F Smithuis JP Guthmann K Barnes HY Myint M Adjuik P Olliaro S Pukrittayakamee S Looareesuwan TT Hien J Farrar F Nosten NP Day NJ White, Antimicrob Agents Chemother 2004 48 4271 4280 15504852 10.1128/AAC.48.11.4271-4280.2004
22. Comparison of different artemisinin-based combinations for the treatment of Plasmodium falciparum malaria in children in Kigali, Rwanda, an area of resistance to sulfadoxine-pyrimethamine: artesunate plus sulfadoxine/ pyrimethamine versus artesunate plus sulfamethoxypyrazine/pyrimethamine. S Rulisa JP Gatarayiha T Kabarisa G Ndayisaba, Am J Trop Med Hyg 2007 77 612 616 17978058
23. A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethaminealone or combined with artesunate or amodiaquine in uncomplicated malaria. FP Mockenhaupt S Ehrhardt SY Dzisi J Teun Bousema N Wassilew J Schreiber SD Anemana JP Cramer RN Otchwemah RW Sauerwein TA Eggelte U Bienzle, Trop Med Int Health 2005 10 512 520 10.1111/j.1365-3156.2005.01427.x 15941413
24. Efficacy and effectiveness of the combination of sulfadoxine/ pyrimethamine and a 3-day course of artesunate for the treatment of uncomplicated falciparum malaria in a refugee settlement in Zambia. E Depoortere JP Guthmann J Pressé N Sipilanyambe E Nkandu S Balkan PE de Pécoulas D Legros, Trop Med Int Health 2005 10 139 145 10.1111/j.1365-3156.2004.01363.x 15679556
25. Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. CE Rwagacondo F Niyitegeka J Sarushi C Karema V Mugisha JC Dujardin C Van Overmeir J van den Ende U D'Alessandro, Am J Trop Med Hyg 2003 68 743 747 12887037
26. Prevalence of point mutations in the dihydrofolate reductase and dihydrofolate synthetase genes of Plasmodium falciparum isolates from India and Thailand: a molecular epidemiologic study. S Biswas A Escalante S Chaiyaroj P Angkasekwinai AA Lal, Trop Med Int Health 2000 10 773 743
27. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. T Triglia AF Cowman, Proc Natl Acad Sci USA 1994 91 7149 7153 8041761 10.1073/pnas.91.15.7149
28. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. DR Brooks P Wang M Read WM Watkins PF Sims JE Hyde, Eur J Biochem 1994 224 397 405 10.1111/j.1432-1033. 1994.00397.x 7925353
29. History, dynamics, and public health importance of malaria parasite resistance. AO Talisuna P Bloland U D'Alessandro, Clin Microbiol Rev 2004 17 235 254 14726463 10.1128/CMR.17.1.235-254.2004
30. Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. G Dorsey C Dokomajilar M Kiggundu SG Staedke MR Kamya PJ Rosenthal, Am J Trop Med Hyg 2004 71 758 763 15642967
31. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. NJ White PL Olliaro, Parasitol Today 1996 12 399 401 10.1016/0169-4758(96)10055-7 15275291
32. Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment. P Olliaro L Pinoges F Checchi M Vaillant JP Guthmann, Trop Med Int Health 2008 13 83 90 18291006
33. Asymptomatic parasitaemia as a risk factor for symptomatic malaria in a cohort of Ugandan children. D Njama-Meya MR Kamya G Dorsey, Trop Med Int Health 2004 9 862 868 10.1111/j.1365-3156.2004.01277.x 15303990
34. Uncommon asymptomatic Plasmodium falciparum infections in Gabonese children. MA Missinou B Lell PG Kremsner, Clin Infect Dis 2003 36 1198 1202 10.1086/374555 12715318
35. Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. D Francis SL Nsobya A Talisuna A Yeka MR Kamya R Machekano C Dokomajilar PJ Rosenthal G Dorsey, J Infect Dis 2006 193 978 986 10.1086/500951 16518760
36. Differences in human antibody reactivity to Plasmodium falciparum variant surface antigens are dependent on age and malaria transmission intensity in northeastern Tanzania. LS Vestergaard JP Lusingu MA Nielsen BP Mmbando D Dodoo BD Akanmori M Alifrangis IC Bygbjerg MM Lemnge T Staalsoe L Hviid TG Theander, Infect Immun 2008 76 2706 2714 18250179 10.1128/IAI.01401-06
37. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. AA Djimdé OK Doumbo O Traore AB Guindo K Kayentao Y Diourte S Niare-Doumbo D Coulibaly AK Kone Y Cissoko M Tekete B Fofana A Dicko DA Diallo TE Wellems D Kwiatkowski CV Plowe, Am J Trop Med Hyg 2003 69 558 563 14695097
38. Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum. A Enevold WM Nkya M Theisen LS Vestergaard AT Jensen T Staalsoe TG Theander IC Bygbjerg M Alifrangis, Malar J 2007 6 153 18021388 10.1186/1475-2875-6-153
39. From chloroquine to artemisinin-based combination therapy: the Sudanese experience. EM Malik TA Mohamed KA Elmardi RM Mowien AH Elhassan SB Elamin AA Mannan ES Ahmed, Malar J 2006 5 65 16879742 10.1186/1475-2875-5-65
40. Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study. D Zurovac M Ndhlovu AK Rowe DH Hamer DM Thea RW Snow, BMJ 2005 331 734 16195289 10.1136/bmj.331.7519. 734
41. Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study. D Zurovac M Ndhlovu N Sipilanyambe P Chanda DH Hamer JL Simon RW Snow, Malar J 2007 6 31 17367518 10.1186/1475-2875-6-31
42. Translation of artemether-lumefantrine treatment policy into paediatric clinical practice: an early experience from Kenya. D Zurovac J Njogu W Akhwale DH Hamer RW Snow, Trop Med Int Health 2008 3 99 107
43. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. G Dorsey S Staedke TD Clark D Njama-Meya B Nzarubara C Maiteki-Sebuguzi C Dokomajilar MR Kamya PJ Rosenthal, JAMA 2007 297 2210 2219 10.1001/jama.297.20.2210 17519410
44. Assessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian random-effects meta-analysis. FH Jansen E Lesaffre LK Penali MJ Zattera H Die-Kakou E Bissagnene, Am J Trop Med Hyg 2007 77 1005 1009 18165512